1. An early-stage Biogen or Regeneron, focused on neurological and immune system therapies.

2. A future Amgen or Gilead, currently developing innovative drugs for brain and immune conditions.

• Taldefgrobep alfa (BHV-2000): A novel myostatin inhibitor therapy in development for the treatment of spinal muscular atrophy (SMA).
• BHV-7000: A Kv7 activator drug candidate being developed for the treatment of epilepsy.
• BHV-1300: An anti-C5aR antagonist designed as a potential treatment for autoimmune and inflammatory diseases.

Biohaven Ltd. (BHVN) is a clinical-stage biopharmaceutical company. Companies in this stage primarily focus on the research and development of drug candidates rather than direct commercial sales of approved products to end-users, pharmacies, or hospitals.

Therefore, Biohaven's "major customers" are typically other pharmaceutical companies that acquire or license its drug candidates and intellectual property for further development and commercialization.

The most significant and publicly known transaction involving the sale of Biohaven's developed assets was the sale of its calcitonin gene-related peptide (CGRP) migraine franchise (including Nurtec ODT and zavegepant) to Pfizer Inc. (NYSE: PFE) in 2022. In this context, Pfizer Inc. acted as a major acquirer of Biohaven's commercialized products and associated rights.

Vlad Coric, M.D. Chairman & Chief Executive Officer

Dr. Coric has served as CEO and director of Biohaven since its formation, becoming Board Chair on September 28, 2022. He spearheaded the sale of Biohaven Pharmaceutical Holding Company Ltd. (the "Former Parent") to Pfizer in 2022 for approximately $13 billion. Prior to Biohaven, he led drug development at Bristol-Myers Squibb from 2007–2015, where he was involved in programs such as Opdivo and Yervoy. He has also served as an Associate Clinical Professor of Psychiatry at Yale School of Medicine since 2001. He received the Ernst & Young Entrepreneur of the Year 2018 Award in the New York region.

Matthew Buten Chief Financial Officer

Mr. Buten possesses over 20 years of experience in healthcare investing and more than 15 years as an advisor in investment banking, structuring deals for both small and large capitalization companies.

Bruce D. Car, DVM, Ph.D., DACVP Chief Scientific Officer

Dr. Car joined Biohaven on August 1, 2022. Before Biohaven, he was Chief Scientific Officer at Agios Pharmaceuticals from January 2020. He previously spent 25 years at Bristol-Myers Squibb (BMS) and its legacy companies, where he worked across various therapeutic areas and drug modalities.

Cliff Bechtold, M.S. President & General Manager, Biohaven Ireland, Chief Compliance Officer

Mr. Bechtold serves as President & General Manager for Biohaven Ireland and Chief Compliance Officer.

Kimberly Gentile Senior Vice President, Clinical Operations

Ms. Gentile holds the position of Senior Vice President, Clinical Operations.

The key risks to Biohaven Ltd.'s business include clinical trial failures and regulatory hurdles, its financial position and ongoing need for additional capital, and intense competition and intellectual property challenges.

1. Clinical Trial Failures and Regulatory Hurdles: As a clinical-stage biopharmaceutical company, Biohaven's success is heavily reliant on the successful development and regulatory approval of its product candidates. Clinical trials are inherently expensive, time-consuming, and carry uncertain outcomes. The company has faced significant setbacks, including the U.S. Food and Drug Administration's (FDA) rejection of its rare disease drug troriluzole for spinocerebellar ataxia (SCA) due to concerns regarding study design and potential biases in real-world evidence. This rejection led to a substantial reduction in the company's research and development spending. Furthermore, Biohaven's pipeline drug BHV-7000 (Opakalim) failed to meet its primary endpoint in a pivotal Phase II/III trial for bipolar disorder, resulting in the discontinuation of its psychiatric development program. Regulatory delays and challenges can severely impede the company's ability to bring therapies to market. The company is also navigating legal challenges, including class-action lawsuits alleging misleading statements about its drug pipeline's regulatory prospects and efficacy.
2. Financial Position and Need for Additional Capital: Biohaven has a limited operating history and has consistently incurred significant operating losses since its inception, with expectations of continued substantial losses and no guarantee of future profitability. The company exhibits a rapid cash burn rate and negative free cash flow. The inability to secure additional capital when necessary could force the company to scale back operations and growth initiatives. Biohaven reported a net loss of $738.8 million in 2025. The company's cash runway is a notable concern, creating urgency for successful near-term clinical milestones and FDA approvals. Recent secondary offerings have been conducted to raise capital.
3. Intense Competition and Intellectual Property Risks: Biohaven operates within a highly competitive and rapidly evolving industry. The company must effectively navigate this landscape and differentiate its product candidates from those of competitors, including potential biosimilars. Significant competition exists in specific therapeutic areas, such as KV7 channel activators, where Biohaven lags behind rivals like Xenon. Risks related to intellectual property include the potential for losing market exclusivity earlier than anticipated, challenges in obtaining necessary licenses from third parties, patent terms that may not provide adequate exclusivity, and the risk of third parties initiating legal proceedings alleging intellectual property infringement. Additionally, there is an ongoing legal dispute concerning alleged misappropriation of trade secrets related to Biohaven's proprietary MODA technology, which could impact its intellectual property assets.

Biohaven Ltd. (BHVN) is a clinical-stage biopharmaceutical company developing therapies for neurological and immunoscience diseases. The company's main product candidates and their addressable markets are as follows:

• Troriluzole (for Spinocerebellar Ataxia (SCA)): There are approximately 15,000 patients with SCA in the U.S. and 24,000 in Europe and the UK, with no currently approved treatments for the disease.
• Opakalim (BHV-7000) (for epilepsy and major depressive disorder (MDD)): Biohaven estimates the market for MDD to include 21 million patients and the epilepsy market to include approximately 3.5 million patients.
• BHV-2100 (for migraine and neuropathic pain): The market for migraine affects 40 million U.S. patients and 1 billion globally.
• Taldefgrobep alfa (BHV-2000) (for Spinal Muscular Atrophy (SMA) and obesity): SMA affects approximately 1 in 11,000 births in the U.S.
• BHV-1300 (IgG degrader for Graves' disease and other autoimmune conditions) and BHV-1400 (TRAP degrader for IgA nephropathy): Biohaven estimates a market opportunity of approximately $15 billion for its degrader platforms, covering multiple disease indications, including rheumatoid arthritis and cardiomyopathy.
• BHV-8000 (TYK2/JAK1 inhibitor for early Parkinson's disease and other neuroinflammatory disorders).

Specific dollar-value market sizes for each of Biohaven's individual pipeline products are not consistently available in the provided information, often detailed by patient population or broad market categories rather than precise revenue projections.

Biohaven Ltd. (BHVN), a clinical-stage biopharmaceutical company, anticipates its future revenue growth over the next 2-3 years to be driven by the advancement and potential commercialization of key investigational therapies in its pipeline. As the company currently has no marketed products generating revenue, all future growth hinges on successful clinical development and regulatory approvals.

Here are the expected drivers of future revenue growth:

1. Opakalim (BHV-7000) for Focal Epilepsy: Biohaven's Kv7 ion channel activator, opakalim (BHV-7000), is in pivotal studies for focal epilepsy and is considered a significant potential revenue driver. The company expects to present topline results from the first pivotal trial for opakalim in the second half of 2026. Analysts have noted opakalim's promising efficacy and safety profile, suggesting a competitive advantage, especially compared to competitor products with meaningful safety disadvantages.

2. Taldefgrobep alfa for Obesity: Biohaven initiated a Phase 2 proof-of-concept study for taldefgrobep alfa in obesity during the fourth quarter of 2025, with topline results anticipated in the second half of 2026. This therapy is designed to reduce fat mass while increasing lean muscle and bone density, aiming to redefine weight loss and address limitations of existing treatments.

3. Lead TRAP™ and MoDE™ Degraders for Immune-Mediated Diseases: Biohaven's innovative extracellular protein degrader platforms (MoDE and TRAP) are central to its long-term strategy in inflammation and immunology. Key programs expected to advance towards pivotal studies and potentially contribute to future revenue include:

   • BHV-1400 (Gd-IgA1 TRAP Degrader) for IgA Nephropathy (IgAN): A pivotal study for BHV-1400 in IgAN is slated to begin in the first quarter of 2026.
   • BHV-1300 (IgG MoDE Degrader) for Graves' Disease: The initiation of a pivotal study for BHV-1300 in Graves' disease is expected in the second half of 2026.
   These degraders have demonstrated deep and rapid target reductions in early clinical studies.

Share Repurchases

• Biohaven Ltd. has not reported any share repurchases over the last 3-5 years, with financial reports indicating no purchases of registered equity securities during the period.
• The number of shares outstanding has generally increased from 35.82 million in 2021 to approximately 105.87 million as of March 11, 2026, indicating share dilution rather than repurchases.

Share Issuance

• In April 2024, Biohaven completed an underwritten public offering of 6,451,220 common shares, generating gross proceeds of approximately $264.5 million.
• The company raised approximately $269.9 million through public equity offerings in October 2024.
• In November 2025, Biohaven closed an underwritten public offering of about 26.8 million common shares, including the full exercise of underwriters' options, resulting in gross proceeds of approximately $200 million.
• Subsequent to December 31, 2025, an additional 17.2 million common shares were issued and sold for net proceeds of $178.9 million.

Inbound Investments

• Institutional investors collectively purchased approximately $624.02 million worth of Biohaven's stock in the last 24 months.

Outbound Investments

• Biohaven made a $42.7 million payment to Knopp Biosciences LLC in May 2024, to settle a 2025 Additional Consideration True-Up liability connected to an amendment to their Membership Interest Purchase Agreement.

Capital Expenditures

• Biohaven's capital expenditures were $4.05 million in 2025, $3.05 million in 2024, $6.07 million in 2023, $0.94 million in 2022, and $1.10 million in 2021.
• As a clinical-stage biopharmaceutical company, capital expenditures are primarily focused on supporting its internal research and development programs and related infrastructure for developing therapies for neurological and immunoscience diseases.